- Home
- RARE vs CBZ Comparison
RARE vs CBZ Comparison
Compare RARE & CBZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- CBZ
- Stock Information
- Founded
- RARE 2010
- CBZ 1987
- Country
- RARE United States
- CBZ United States
- Employees
- RARE N/A
- CBZ N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- CBZ Business Services
- Sector
- RARE Health Care
- CBZ Consumer Discretionary
- Exchange
- RARE Nasdaq
- CBZ Nasdaq
- Market Cap
- RARE 3.5B
- CBZ 4.0B
- IPO Year
- RARE 2014
- CBZ N/A
- Fundamental
- Price
- RARE $39.91
- CBZ $73.76
- Analyst Decision
- RARE Strong Buy
- CBZ Strong Buy
- Analyst Count
- RARE 15
- CBZ 1
- Target Price
- RARE $90.53
- CBZ $86.00
- AVG Volume (30 Days)
- RARE 1.1M
- CBZ 566.6K
- Earning Date
- RARE 07-31-2025
- CBZ 07-30-2025
- Dividend Yield
- RARE N/A
- CBZ N/A
- EPS Growth
- RARE N/A
- CBZ N/A
- EPS
- RARE N/A
- CBZ 1.55
- Revenue
- RARE $590,689,000.00
- CBZ $2,157,189,000.00
- Revenue This Year
- RARE $18.94
- CBZ $58.65
- Revenue Next Year
- RARE $28.93
- CBZ $5.74
- P/E Ratio
- RARE N/A
- CBZ $47.74
- Revenue Growth
- RARE 33.46
- CBZ 32.27
- 52 Week Low
- RARE $29.59
- CBZ $62.66
- 52 Week High
- RARE $60.37
- CBZ $90.13
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- CBZ 59.85
- Support Level
- RARE $35.51
- CBZ $70.04
- Resistance Level
- RARE $38.19
- CBZ $72.55
- Average True Range (ATR)
- RARE 1.58
- CBZ 1.80
- MACD
- RARE 0.20
- CBZ 0.51
- Stochastic Oscillator
- RARE 98.43
- CBZ 98.21
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CBZ CBIZ Inc.
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.